Small molecule · developed by Galmed Pharmaceuticals
Aramchol is a small-molecule bile acid derivative administered orally. It is studied in non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, and primary sclerosing cholangitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04104321 | Phase 3 | Nonalcoholic Steatohepatitis (NASH) | Suspended | EOCN |
| NCT06095986 | Phase 2 | Primary Sclerosing Cholangitis | Withdrawn | EOCN |
| NCT02279524 | Phase 2 | Fatty Liver | Completed | EOCN |
| NCT04480827 | Phase 1 | Hepatic Impairment | Completed | EOCN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fatty LiverHepatic ImpairmentLiver DiseasesLiver FibrosesNon-Alcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)Primary Sclerosing Cholangitis
Updated Oct 3, 2026. Something wrong or missing? Report it on the EOCN page.
See EOCN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EOCN catalysts and pipeline →